metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Development of hepatic steatosis in liver transplant recipient patients.
Información de la revista
Vol. 29. Núm. S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(febrero 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(febrero 2024)
Acceso a texto completo
Development of hepatic steatosis in liver transplant recipient patients.
Visitas
215
Javier I. Carrillo-Rojas1, Sarahi Ontiveros-López1, Martín Rivera-Huizar1, Nallely Bueno-Hernández2, María C. Baxin Domínguez1, Areli Torres-Castro1
1 Servicio de Gastroenterología, Hospital de Especialidades, Centro Médico Nacional La Raza, Ciudad de México
2 Departamento de Investigación, Clínica de Enfermedad Inflamatoria Intestinal, Hospital General de México “Eduardo Liceaga”
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Tablas (1)
Table 1. Characteristics of people who developed hepatic steatosis.
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S2

Abstracts Asociación Mexicana del Hígado (AMH) 2023

Más datos
Introduction and Objectives

It has been reported that up to 39.7% of liver transplant recipients develop hepatic steatosis at some point during follow-up, with recurrence being more likely than de novo appearance. Specifically in patients previously known to have MAFLD, this condition is favored by the components of the metabolic syndrome (particularly being overweight), to which is added the use of immunosuppressive drugs. The objective is to determine the prevalence of hepatic steatosis by ultrasound in patients receiving liver transplants at the Hospital de Especialidades del Centro Médico Nacional La Raza.

Materials and Patients

In this study were included liver transplant recipients treated in the period from 2017 to 2023 who had a liver ultrasound at least six months after transplantation. The diagnosis of hepatic steatosis was established by an increase in the echogenicity of the liver parenchyma, which is equal to or exceeds the echogenicity of the pancreas.

Results

A sample of 40 patients was analyzed, 19 men (47.5%) and 21 women (52.5%), with age of 52.05 ±10.49 years. The most common causes of liver disease were hepatitis C virus infection (32.5%), MAFLD (17.5%), and autoimmune hepatitis (15%). The most frequent comorbidity was diabetes (20%)(Chart 1). Hepatic steatosis was found in 25% of cases (50% men and 50% women) (Graph 1). The most frequent etiology of liver disease in patients who developed steatosis was MAFLD (20%), while in those who did not develop steatosis it was HCV infection (40%), without statistical significance. When compared with patients without steatosis, there were no statistically significant differences in post-transplant weight and BMI (69.2 vs. 67.0 kg, p= 0.601; BMI 26.0 vs. 25.0, p=0.529) or pre-transplant MELD (14.3 vs. 16.4, p= 0.251)

Conclusions

In our study, the prevalence of steatosis found was similar to that reported by other authors. They have not evidenced statistically significant differences in age, gender, comorbidities, anthropometry, or etiology of cirrhosis. Patients need close monitoring to identify the development of this complication in a timely manner.

Texto completo

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Table 1.

Characteristics of people who developed hepatic steatosis.

Variable  Patients who developed steatosis (%) n= 10 (24.3)  Patients who didn't develop steatosis (%) n= 31 (75.6)  p value 
Sex      0.023 
Male  8 (80)  12 (38.7)   
Female  2 (20  19 (61.2)   
Age  52.4±12.3  51.3±10.3  0.818 
Comorbidities       
Diabetes  4 (40)  4 (12.9)  0.060 
Hypertension  1 (10)  2 (6.4)  0.708 
Hypothyroidism  0 (0)  4 (12.9)  0.232 
Etiology      0.192 
MASLD  4 (40)  3 (9.6)   
Autoimmune hepatitis  2 (20)  5 (13.8)   
Primary biliar cholangitis  1 (10)  2 (6.4)   
Primary sclerosing cholangitis  0 (0)  1 (3.2)   
Ethylism  0 (0)  2 (6.4)   
Chronic hepatitis C virus infection  2 (20)  11 (35.4)   
AIH-PBC overlap  0 (0)  4 (12.9)   
Polycystic disease  0 (0)  3 (9.6)   
Cryptogenic  1 (10)  0 (0)   
BMI pre-transplant  27.5±3.7  24.0±3.1  0.032 
BMI pre-transplant interpretation      0.049 
Low  0 (0)  2 (6.4)   
Normal  3 (30)  19 (61.2)   
Overweight  4 (40)  2 (6.4)   
Class 1 obesity  3 (30)  1 (3.2)   
BMI post transplant  27.6±3.7  24.8±2.9  0.054 
BMI post- trasplant interpretation      0.162 
Low  0 (0)  0 (0)   
Normal  2 (20)  14 (45.1)   
Overweight  6 (60)  16 (51.6)   
Obesity  2 (20)  1 (3.2)   

MASLD, metabolic dysfunction-associated steatotic liver disease; AIH, autoimmune hepatitis; PBC, primary biliary colangitis; BMI, body mass index.

Figure 1. Prevalence of steatosis in patients receiving liver transplantation.

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos